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Abstract
Background: While the United States has the largest number of children with type 1 diabetes mellitus, less is
known regarding adult-onset disease. The present study utilizes nationwide data to compare the incidence of type
1 diabetes in youth (0–19 years) to that of adults (20–64 years).
Methods: In this longitudinal study, the Clinformatics® Data Mart Database was used, which contains information
from 61 million commercially insured Americans (years 2001–2015). Incidence rates and exact Poisson 95%
confidence intervals were calculated by age group, sex, census division, and year of diagnosis. Changes in rates
over time were assessed by negative binomial regression.
Results: Overall, there were 32,476 individuals who developed type 1 diabetes in the cohort. The incidence rate
was greatest in youth aged 10–14 years (45.5 cases/100,000 person-years); however, because adulthood spans over
a longer period than childhood, there was a greater number of new cases in adults than in youth (n = 19,174
adults; n = 13,302 youth). Predominance in males was evident by age 10 and persisted throughout adulthood. The
male to female incidence rate ratio was 1.32 (95% CI 1.30–1.35). The incidence rate of type 1 diabetes in youth
increased by 1.9% annually from 2001 to 2015 (95% CI 1.1–2.7%; P < 0.001), but there was variation across regions.
The greatest increases were in the East South Central (3.8%/year; 95% CI 2.0–5.6%; P < 0.001) and Mountain divisions
(3.1%/year; 95% CI 1.6–4.6%; P < 0.001). There were also increases in the East North Central (2.7%/year; P = 0.010),
South Atlantic (2.4%/year; P < 0.001), and West North Central divisions (2.4%/year; P < 0.001). In adults, however, the
incidence decreased from 2001 to 2015 (−1.3%/year; 95% CI −2.3% to −0.4%; P = 0.007). Greater percentages of
cases were diagnosed in January, July, and August for both youth and adults. The number of new cases of type 1
diabetes (ages 0–64 years) in the United States is estimated at 64,000 annually (27,000 cases in youth and 37,000
cases in adults).
Conclusions: There are more new cases of type 1 diabetes occurring annually in the United States than previously
recognized. The increase in incidence rates in youth, but not adults, suggests that the precipitating factors of
youth-onset disease may differ from those of adult-onset disease.
Keywords: Type 1 diabetes mellitus, Incidence study, Trends, Age differences
* Correspondence: maryroge@umich.edu
1Department of Internal Medicine, University of Michigan, Building 16, Room
422 W North Campus Research Complex, 2800 Plymouth Road, Ann Arbor,
Michigan 48109-2800, USA
2Institute of Healthcare Policy and Innovation, University of Michigan, Ann
Arbor, Michigan, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rogers et al. BMC Medicine  (2017) 15:199 
DOI 10.1186/s12916-017-0958-6
Background
Of any country, the United States has the largest num-
ber of children with type 1 diabetes in the world [1].
While there is no reporting system that captures all
cases nationwide, there is active surveillance in certain
areas of the country, provided by the SEARCH for
Diabetes in Youth Study [2], for cases occurring in youth
(ages < 20 years). This study provides invaluable infor-
mation regarding the characteristics of youth with type 1
diabetes, but it does not cover the entire United States
nor does it explore adult-onset type 1 diabetes.
Data on disease incidence rates are crucial, providing
the underpinnings necessary for etiologic investigations
and essential health services. This is of particular im-
portance for type 1 diabetes since its incidence is rising
in various countries worldwide [3]. Moreover, while type
1 diabetes has historically been characterized as having
an onset during childhood, there has been recent recog-
nition that the actual number of new cases of type 1 dia-
betes in adults has been underreported [4]. A study from
the United Kingdom indicated that the numbers of new
cases are evenly distributed above and below the age of
30 [5], accentuating the statement by the American
Diabetes Association, that “[t]he precise incidence of
new-onset type 1 diabetes in those over 20 years of age is
unknown” [6].
In the United States, the advent of large databases from
health insurance companies that offer nationwide
coverage affords an opportunity to investigate country-
wide patterns of disease. In 2015, 70% of people in the
United States under the age of 65 years received their
healthcare through private insurance [7]. Using such a
national database, we were particularly interested in the
incidence of type 1 diabetes of acute onset, rather than
slowly developing disease, which is referred to as latent
autoimmune diabetes of adult-onset (LADA) [8]. To our
knowledge, this is the first nationwide report of incidence
rates of type 1 diabetes mellitus across time and place
within the United States for both children and adults.
Methods
Subjects
In this longitudinal study, data were obtained through de-
identified information retrieved from the Clinformatics®
Data Mart Database (OptumInsight, Eden Prairie, MN)
from a large, national, United States commercial health
insurance provider. The longitudinal database contained
61 million beneficiaries who received both medical and
drug coverage. The integrated enrollment, medical, and
prescription claims data included information regarding
both outpatient and inpatient medical services (e.g., clinic
visits, rural health visits, emergency room visits, hos-
pitalizations, etc.) with diagnoses and procedures.
Pharmacy files, which included medication prescriptions,
and member files, which contained general demographic
information, were also obtained. The files contained
information from claims submitted from January 1, 2001,
through June 30, 2015.
We selected patients with newly diagnosed (incident)
type 1 diabetes mellitus. Patients with type 1 diabetes
were defined as those individuals with a minimum of
two diagnoses indicating type 1 diabetes (ICD-9-CM
codes: 250.01, 250.03, 250.11, 250.13, 250.21, 250.23,
250.31, 250.33, 250.41, 250.43, 250.51, 250.53, 250.61,
250.63, 250.71, 250.73, 250.81, 250.83, 250.91, 250.93)
and at least one outpatient prescription filled for insulin
(insulins 682008, 68200800). The use of administrative
data (specifically, ICD-9 codes from billing data) to iden-
tify individuals with type 1 diabetes was reported to have
a sensitivity of 96.7% in children under 10 years of age
and of 96.9% in persons 10 years of age and older
(specificity 99.8% and 99.7%, respectively) [9].
Individuals with gestational diabetes (ICD-9-CM code:
648.8×) were excluded. We also excluded individuals
aged 65 years or older because the eligibility for
Medicare Advantage, a government health insurance
program principally for adults aged 65 years and older,
varied over the time period of this study.
To detect incident (as opposed to existing) cases, we
required at least 6 months (≥182 days) of insurance
coverage prior to the first recorded diagnosis of type 1
diabetes. That is, we required that there be at least
6 months without any record of type 1 diabetes before
the first diagnosis was reported; infants (with diagnoses
codes and insulin use) were defined as having incident
type 1 diabetes even if covered for less than 6 months.
For adults aged 20–64 years at diagnosis, we instituted
additional procedures to distinguish type 1 from type 2
diabetes. First, we excluded individuals who used any anti-
diabetic drug (insulin, biguanides, dipeptidyl peptidase-4
inhibitors, incretin mimetics, meglitinides, sulfonylureas,
and/or thiazolidinediones) during their first 6 months of
healthcare coverage. This removed individuals being
treated for type 2 diabetes at the time of study entry and
individuals with pre-existing type 1 diabetes. The second
criterion for adults was that insulin use after diagnosis
was continuous over time. Individuals were excluded if
they had received prescription refills for insulin but later
discontinued use for at least 6 months even though they
were still eligible for drug coverage. Third, because there
may be uncertainty regarding the type of diabetes when
first diagnosed, we allowed a window around the first
diagnosis date during which various antidiabetic agents
may be used. However, adults who used oral antidiabetic
medications (biguanides, dipeptidyl peptidase-4 inhibitors,
incretin mimetics, meglitinides, sulfonylureas, and/or
thiazolidinediones) 6 months before or after the first type
1 diabetes diagnosis date were excluded. This primarily
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removed those with long-standing type 2 diabetes who
were adding insulin to their regimen.
We conducted two sensitivity analyses, each using a
different classification for type 1 diabetes. In the first
sensitivity analysis, we mirrored the Vanderloo algorithm
[10]. That is, all incident cases under the age of 10 years
were selected. These cases had at least two type 1 dia-
betes diagnoses with an outpatient prescription for insu-
lin filled. For individuals of 10 years of age or above,
incident cases were those who used insulin only within
730 days after the date of their first diagnosis. As before,
we removed existing cases during their first 6 months of
healthcare coverage (to focus on incident cases) and we
stipulated that, once started on insulin, they did not dis-
continue use.
In the second sensitivity analysis, we retained all the
principal requirements for classification as described in
our main analysis (above). However, we further re-
stricted the definition of type 1 diabetes; only those
individuals who had a rapid onset (at any age) were in-
cluded. A rapid onset was defined as the occurrence of
the first diagnosis date and the first insulin prescription
filled within 6 months of each other.
Analyses
Incidence rates were calculated from the count of
incident cases (numerator) and the person-years of ob-
servation (denominator). Rates and exact Poisson 95%
confidence intervals (CIs) were calculated by age group,
sex, census division, and year of diagnosis. Nine divisions
were defined by the Census Bureau as New England,
Middle Atlantic, East North Central, West North
Central, South Atlantic, East South Central, West South
Central, Mountain, and Pacific [11]. Unadjusted age-
specific rates were reported so that the actual numbers
of persons affected (per population) are available for
health services planners and for linkage in future investi-
gations. To assess changes in incidence rates over time,
negative binomial regression was used with robust
standard errors, offset by the natural logarithm of
person-years of observation. Because there was prior
evidence of seasonal differences in incidence [12], we
also plotted the percentage of incident cases by month
over the entire study period (2001–2015) and differences
in counts were assessed through Poisson regression.
Direct standardization by age, sex, and race was used to
adjust incidence rates over time, using the pooled popu-
lation 2001–2015 as the standard. Alpha was set at 0.05,
two-tailed. All analyses were conducted in Stata/MP
version 14.2.
Calculations were performed to extrapolate to the en-
tire United States population using Census data from
the year 2015 [7]. Our cohort of 61 million privately
insured Americans is a sample of the 214 million
individuals covered under commercial healthcare in-
surers annually in the United States [7]. Therefore, we
extrapolated our sample to the reference population under
private healthcare coverage using age-specific rates. Next,
we estimated the number of incident cases for (1) individ-
uals who receive government (Medicaid and military)
health insurance and (2) the uninsured, through direct
standardization. Because the age and racial distributions
of these populations differ from the commercially insured
population, we first calculated age- and race-specific inci-
dence rates of type 1 diabetes and applied these to the re-
spective distributions for those receiving government
insurance and the uninsured.
Results
The database contained 61,795,350 individuals who had
private healthcare insurance from January 2001 through
June 2015. Of these people, 437,688 had two type 1 dia-
betes diagnoses recorded and at least one prescription
filled for insulin. Overall, there were 32,476 individuals
who developed type 1 diabetes in the study cohort. The
incidence rate was 22.9 cases per 100,000 person-years
(95% CI 22.7/100,000 to 23.2/100,000) for individuals aged
0–64 years. The mean length of health coverage for the in-
cident cases was 5.1 years (SD, 3.2 years); the median
length of health coverage was 4.3 years (interquartile
range, 2.5–7.0 years).
Incidence by age and sex
Incident cases included 13,302 youth (0–19 years) and
19,174 adults (20–64 years). The incidence rate of type 1
diabetes was greatest in youth aged 10–14 years, at 45.5
cases per 100,000 person-years (Table 1). The annual in-
cidence rate of type 1 diabetes was 34.3 per 100,000 per-
sons for ages 0–19 years and 18.6 per 100,000 persons
for ages 20–64 years in this cohort.
Type 1 diabetes developed more often in males than
in females (Fig. 1), with an incidence of 26.1/100,000
person-years (95% CI 25.7/100,000 to 26.5/100,000) and
19.7/100,000 person-years (95% CI 19.4/100,000 to 20.0/
100,000; P < 0.001), respectively. The male to female in-
cidence rate ratio was 1.32 (95% CI 1.30–1.35). The pre-
dominance in males was evident by age 10 and persisted
throughout adulthood.
In the 6 month period around diagnosis, ketoacidosis
occurred in a small percentage of cases, ranging from
2.5% in those aged 60–64 years to 15.2% in those aged
under 5 years (Table 1). Prescriptions for emergency glu-
cagon kits were filled most often during childhood (e.g.,
79.4% in children aged 5–9 years at diagnosis) and less
often in adults (e.g., 4.8% for those aged 50–54 years).
For most children and adults, the first insulin prescrip-
tion was filled within 6 months of the first diagnosis
(>90% in youth; > 80% in older adults).
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Incidence over time
The incidence of type 1 diabetes in youth (0–19 years)
increased by 1.9% each year from 2001 to 2015 (95% CI
1.1–2.7%; P < 0.001). However, there was variation by div-
ision of the country (Figs. 2, 3, 4, and 5). The greatest
increase was in the East South Central division (3.8%/year;
95% CI 2.0–5.6%; P < 0.001). The next greatest increase
occurred in the Mountain division (3.1%/year; 95% CI
1.6–4.6%; P < 0.001). There were also increases in the East
North Central (2.7%/year; 95% CI 0.7–4.9%; P = 0.010),
South Atlantic (2.4%/year; 95% CI 1.3–3.4%; P < 0.001),
and West North Central divisions (2.4%/year; 95% CI 1.2–
3.6%; P < 0.001). There were no significant linear increases
in incidence in the Middle Atlantic (P = 0.441), New Eng-
land (P = 0.370), West South Central (P = 0.229), or Pa-
cific divisions (P = 0.558). Although there was no
significant linear increase in New England youth, the rates
fluctuated considerably over time. CIs for the plotted rates
are given in Additional file 1: Tables S1–S4.
For adult-onset type 1 diabetes, there was a de-
crease in the incidence from 2001 to 2015 (−1.3%/year;
95% CI −2.3% to −0.4%; P = 0.007). This decrease was
driven by the Pacific division (−3.7%/year; 95% CI −5.3%
to −1.9%; P < 0.001). The other regions did not experience
a significant linear trend in incidence rates in adults. How-
ever, there was a spike in incidence in the year 2006 for
adults in the East South Central region (Fig. 4); the inci-
dence was elevated in both men (68.8 per 100,000) and
women (62.1 per 100,000).
After adjustment for age, sex, and race, the increase in
the incidence rates of type 1 diabetes from 2001 to 2015
in youth remained. The adjusted incidence rates in-
creased by 0.9% each year in youth (P = 0.009). In adults
aged 20–64 years, the reduction in incidence rates over
time remained after adjustment. There was a 1.9% re-
duction in incidence rates with adjustment (P = 0.026).
Variation in the percentages of incident cases by
month of first diagnosis is shown in Fig. 6. The greatest
percentages of cases were diagnosed in January for both
youth and adults. There were also increased proportions
Table 1 Incidence of type 1 diabetes mellitus and characteristics when first diagnosed by age category, 2001–2015
Age category,
yearsa
Incident cases Incidence rateb Ketoacidosis within 6 months of
diagnosisc
Emergency glucagon kit within
6 months of diagnosisd
Rapid onsete
n n % n % n %
< 5 1944 23.0 (22.0–24.1) 295 15.2% 1318 67.8% 1873 96.3%
5–9 2966 29.9 (28.9–31.0) 362 12.2% 2355 79.4% 2895 97.6%
10–14 4668 45.5 (44.2–46.8) 533 11.4% 3248 69.6% 4499 96.4%
15–19 3724 36.4 (35.3–37.6) 334 9.0% 1713 46.0% 3511 94.3%
20–24 1752 18.0 (17.2–18.9) 140 8.0% 344 19.6% 1608 91.8%
25–29 1841 16.6 (15.8–17.3) 126 6.8% 238 12.9% 1673 90.9%
30–34 1897 15.3 (14.6–16.0) 135 7.1% 201 10.6% 1693 89.2%
35–39 2042 15.9 (15.2–16.6) 164 8.0% 182 8.9% 1788 87.6%
40–44 2148 16.0 (15.3–16.7) 152 7.1% 139 6.5% 1843 85.8%
45–49 2353 17.8 (17.1–18.5) 134 5.7% 116 4.9% 2005 85.2%
50–54 2446 20.0 (19.2–20.8) 108 4.4% 117 4.8% 2063 84.3%
55–59 2424 23.4 (22.5–24.3) 83 3.4% 101 4.2% 2012 83.0%
60–64 2271 29.2 (28.0–30.4) 56 2.5% 66 2.9% 1864 82.1%
Total 32,476 22.9 (22.7–23.2) 2622 8.1% 10,138 31.2% 29,327 90.3%
aAge at first diagnosis
bIncident cases of type 1 diabetes per 100,000 person-years of healthcare coverage (95% confidence interval)
cKetoacidsosis was recorded within 6 months (i.e., ±182 days) of the first diagnosis
dEmergency glucagon kit was filled within 6 months (i.e., ±182 days) of the first diagnosis
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Fig. 1 Incidence rates for type 1 diabetes by age at diagnosis and
sex, United States, 2001–2015
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diagnosed in July and August. For youth, counts of
incident cases were not significantly different in January
versus July (P = 0.177) or August (P = 0.847), but were
different from all the other months (P < 0.001). In adults,
the number of incident cases in January was significantly
greater than any of the other months (P < 0.001 for all
other months). The monthly patterns appeared some-
what similar in youth and adults, although the percent-
age of incident cases in July and August were more
elevated in youth.
Sensitivity analyses
Using the Vanderloo algorithm yielded slightly higher in-
cidence rates of type 1 diabetes, particularly in the older
age categories (Table 2). The overall incidence was 26.1
cases per 100,000 person-years (95% CI 25.8/100,000 to
26.4/100,000). The more restrictive classification of
limiting cases to only those with a rapid onset yielded a
slightly lower incidence of type 1 diabetes (20.7 cases/
100,000 person-years; 95% CI 20.4/100,000 to 20.9/
100,000); the age-specific rates are shown in Table 2.
Extrapolation to the entire population
Overall, for individuals aged 0–64 years, the number of
annual incident cases of type 1 diabetes in the United
States was estimated to be 64,000, regardless of
insurance type. For youth, the number of incident type 1
diabetes cases was estimated to be 27,000 annually
(15,000 with commercial health insurance, 11,000 with
government health insurance, 1000 uninsured). For
adults (20–64 years of age), we estimated 37,000 incident
cases of type 1 diabetes annually in the United States
(24,000 with commercial health insurance, 8000 with
government insurance, and 5000 uninsured).
Discussion
There are more new cases of type 1 diabetes occurring
each year in the United States than previously recognized.
Overall, the number of individuals (0–64 years of age)
who develop type 1 diabetes annually is approximately
64,000 across the entire country. More incident cases of
type 1 diabetes occur in adults than in youth each year,
which is similar to the findings from the United Kingdom
[5]. While the incidence rate is greater in youth, adulthood
extends for a longer time. Thus, this phenomenon might
have been predicted by population dynamics while under-
appreciated in everyday practice. The SEARCH for Dia-
betes in Youth Study estimated that there were 17,900
youth (aged < 20 years) who developed type 1 diabetes in
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Fig. 3 Incidence of type 1 diabetes in Midwestern United States by year
Rogers et al. BMC Medicine  (2017) 15:199 Page 5 of 9
were 13,000 new cases on an annual basis in youth [1].
Our study, using data from the entire United States,
suggests that these figures are likely underestimates. A
possible reason for the difference is that earlier estimates
were based on data from only five states, while our
analysis included data from all 50 states.
Data from Sweden indicate that the incidence of type
1 diabetes is bimodal [14], wherein two spikes in
incidence are observed, one at ages 0–9 years and
another occurring at 50–80 years of age [14]. In our data-
base, there was a spike in incidence at ages 10–14 years,
followed by a decline, and then an upward trend starting
at age 40. Similar findings were reported from the
population-based registry in Turin, Italy [15], wherein a
rise in incidence at ages 10–14, followed by a decline and
a slow increase from age 30 onwards was observed. Simi-
lar to our study, the authors found the same pattern of a
male predominance from age 10 onwards. Others have
also observed such male predominance; a recent review
found that 44 of 54 studies reported male predominance
in adolescents and adults [16]. Populations with higher
incidences of type 1 diabetes overall tend to have greater
male predominance [17]. Studies of sex differences in hor-
monal fluctuations at the time of adrenarche in genetically
predisposed individuals could perhaps provide clues to the
underlying pathogenesis of this disease.
We found that incidence rates of type 1 diabetes in
youth significantly increased with time. The SEARCH
study reported an annual increase of 2.7% from 2002 to
2009 in non-Hispanic white youth [18] and an adjusted
annual increase of 1.8% in all youth between the periods
2002–2003 and 2011–2012 [13]. We found an annual
increase of 1.9% from 2001 to 2015 when measured in
all youth. Of note, the East South Central, Mountain,
Midwest, and South Atlantic regions demonstrated an
increase of 2.4% to 3.8% annually. Variations in the
incidence of childhood type 1 diabetes have also been
observed in Europe, with increases ranging from 0.4% to
7.8% across different regions (the exception being
Catalonia) from 1999 to 2008 [19].
However, we found no increase over time in the inci-
dence of adult-onset cases. With the data available, the
underlying reasons for this cannot be directly determined.
Although both youth- and adult-onset cases are described
as autoimmune in nature, etiologic determinants are still
under investigation in children and have not been thor-
oughly studied in adults. Of note, there was one irregular-
ity, wherein the data indicated a spike in incidence in 2006
in adults of the East South Central region. This could have
been due to differences in diagnosis at that time, factors re-
lated to the particular patients in the region, a recording
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Fig. 5 Incidence of type 1 diabetes in Western United States by year
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anecdotally reported in specific areas [20], but further in-
vestigation would be needed to determine relevant factors.
We found seasonal differences in incidence rates, with
somewhat similar patterns in youth and adults. Seasonal
variation in diagnosis of type 1 diabetes has been widely
reported in the literature and, in general, show peaks in
the winter and troughs in late spring to summer in the
northern hemisphere [12]. Because the etiology is multi-
factorial [21], the significance of such seasonal patterns
is unclear. One report indicated a median of 25 days
(range 2–315 days) from symptom onset to diagnosis in
children [22], but the time period from pathogenesis to
symptom onset is speculative.
Our results provide a clue that the etiologic factors
contributing to pediatric type 1 diabetes differ from
those of adult-onset disease. Incidence rates increased
over time in youth-onset cases while these rates
decreased in adults, suggesting that some precipitating
factors may be different in early- versus later-onset dis-
ease. Moreover, regional variations in incidence suggest
that the etiologic contributors are differentially distrib-
uted across the country.
There are limitations to our investigation. Data regarding
C-peptide and glutamic acid decarboxylase autoantibodies
were only available on a small fraction of cases. Therefore,
the diagnosis was determined through ICD-9-CM diagno-
sis codes and medication use. Validation studies indicate
that the use of diagnosis codes and medications yield a sen-
sitivity of 98.6% for type 1 diabetes [10] and, for diagnosis
codes alone, a positive predictive value of 97.0% for type 1
diabetes [23]. The determination of adult-onset type 1 dia-
betes was more difficult because, in practice, it may be mis-
takenly diagnosed as type 2 diabetes. Therefore, we
instituted additional measures and conducted sensitivity
analyses that restricted the number of adults classified as
having type 1 diabetes. Although adults newly diagnosed
with type 2 diabetes are usually treated with oral agents
and lifestyle measures rather than insulin exclusively, it is
possible that adults with extreme glycemia elevations
and/or contraindications to oral agents would be
treated initially with insulin and would continue to use
insulin exclusively. It is also possible that our definition
in adults may have been too restrictive, because some
individuals with type 1 diabetes may use metformin
[24], although this generally occurs with established
cases of type 1 diabetes and not with newly onset
disease, as assessed herein. Finally, we used standard
diagnosis codes as currently available. For adult-onset
autoimmune diabetes mellitus, there have been recent dis-
cussions regarding reclassification of a subset of adults in
which β-cell failure occurs slowly (LADA) [8, 25]. There is
considerable controversy regarding the use of the term
LADA, as well as suggestions for improving the current
classification of diabetes based on β-cell commonalities
across all presentations of the disease [26, 27]. Population-
based longitudinal studies will be necessary to determine
what fraction of the adult-onset autoimmune cases this
constitutes, although some investigators report LADA to
be much more prevalent than acute-onset type 1 diabetes
[28, 29]. In our study, the focus was on acute-onset cases;
we did not capture LADA cases, although this is of
interest for future studies.
One of the strengths of our study is the use of
integrated medical files to identify cases. In the past, regis-
tries or lists from single sources were used, with capture-
recapture methods to extend ascertainment [4, 18, 30, 31].
The relational database used contained all the different
locations in which patients received services within their
health insurance plan, which included clinician visits
(primary care physicians, specialists, nurse practitioners,
etc.), home health visits, rural health visits, urgent care
visits, ambulance services, hospitalizations (acute care,
long-term, rehabilitation), skilled nursing facilities, mental
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Fig. 6 Month of first diagnosis for type 1 diabetes in the United States, 2001–2015
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dates. The use of such large national databases may
provide exceptional and complimentary information to
studies that utilize existing registries.
Conclusions
More new cases of type 1 diabetes occur each year in
the United States than previously recognized. Incident
cases occurred more often in adults than youth, even
though incidence rates were greater in youth because of
the longer time period encompassing adulthood. From
2001 to 2015, incidence rates of type 1 diabetes
increased in youth, but not uniformly throughout the
country. However, incidence rates decreased over time
in adults. The increase in incidence rates in youth, but
not adults, suggests that the precipitating factors of
youth-adult disease may differ from those of adult-onset
disease. Fluctuations in the incidence of type 1 diabetes
may provide clues to etiology and facilitate the planning
of appropriate health services.
Additional file
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diabetes in patients, ages 20-64 years. (ZIP 26.3 kb)
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Table 2 Sensitivity analyses for the incidence of type 1 diabetes mellitus in the United States by age category, 2001–2015
Vanderloo algorithma Rapid onsetb
Age category, yearsc N, incident cases Incidence rated 95% Confidence intervals N, incident cases Incidence rated 95% Confidence intervals
< 5 1944 23.0 22.0–24.1 1873 22.2 21.2–23.2
5–9 2966 29.9 28.9–31.0 2895 29.2 28.2–30.3
10–14 4466 43.6 42.3–44.8 4499 43.9 42.6–45.2
15–19 3399 33.3 32.1–34.4 3511 34.4 33.2–35.5
20–24 1746 17.9 17.1–18.8 1608 16.5 15.7–17.3
25–29 1943 17.5 16.7–18.3 1673 15.0 14.3–15.8
30–34 2095 16.9 16.2–17.6 1693 13.7 13.0–14.3
35–39 2418 18.8 18.0–19.5 1788 13.9 13.2–14.5
40–44 2741 20.4 19.7–21.2 1843 13.7 13.1–14.4
45–49 3090 23.4 22.5–24.2 2005 15.2 14.5–15.8
50–54 3481 28.4 27.5–29.4 2063 16.9 16.1–17.6
55–59 3436 33.1 32.0–34.3 2012 19.4 18.6–20.3
60–64 3356 43.2 41.7–44.7 1864 24.0 22.9–25.1
Total 37,081 26.1 25.8–26.4 29,327 20.7 20.4–20.9
aAll incident cases < 10 years of age; for those ≥ 10 years, insulin only within 730 days from
diagnosis
bFirst diagnosis of type 1 diabetes and the first insulin prescription filled were within 6 months
cAge at first diagnosis
dIncident cases of type 1 diabetes per 100,000 person-years of healthcare coverage
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